A deal with KdT Ventures is the latest twist in a lengthy saga for the biotech, which was taken private after losing most of its value as a public company.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,